Conquering Diseases

Study Of A Vaccine To Prevent Respiratory Syncytial Virus (Rsv) In Healthy Infants Aged 5 Months To < 8 Months


Seeking healthy infants 5 < 8 months of age for a study to determine whether investigational mRNA vaccines can prevent respiratory syncytial virus (RSV) or human metapneumovirus (hMPV) infection.


Participants in this study will either get one of two doses of the experimental mRNA vaccine or a placebo (looks like the vaccine but contains no medicine). The vaccines will be given as an injection three times over a period of 4 months. After the third and final injection, there will be periodic follow-up visits over 2 years. To be eligible for study, neither infants nor their mothers must not have previously been administered antibodies or a vaccine to prevent RSV or hMPV.

What we're hoping for

We are studying whether an mRNA vaccine is safe and effective in preventing respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections in babies 5< 8 months of age.

Additional Information Identifier: NCT05743881

 Principal Investigator

Katherine  Luzuriaga, MD

UMass Chan Medical School

 Study Contact

Heather  Tarantino



UMass Chan University Campus

55 Lake Ave North 

Worcester,MA 01655